Taking stock of the drug industry, from the lab to the medicine chest

January 3, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe Opinion: Save the Food and Drug Administration by breaking it up Splitting the FDA in two will help rebuild trust and allow the new agencies to focus on what they do best. By Lee D. Cooper STAT+ | Trump's FDA transition team takes shape with former Hahn adviser, courts top Capitol Hill aide Trump's staff is laying the groundwork to prepare for a new FDA commissioner and make their mark at the agency. By Rachel Cohrs Zhang They may be 'miracle' drugs, but obesity meds call for a team approach The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single physician to handle. By Elizabeth Cooney ALAIN JOCARD/AFP via Getty Images STAT+ | Neumora's antidepressant stumbles in first Phase 3 trial readout The drug, navacaprant, failed to show a meaningful improvement in depression scores compared to placebo, the company said. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser